235 related articles for article (PubMed ID: 28925944)
1. Interference of Paraben Compounds with Estrogen Metabolism by Inhibition of 17β-Hydroxysteroid Dehydrogenases.
Engeli RT; Rohrer SR; Vuorinen A; Herdlinger S; Kaserer T; Leugger S; Schuster D; Odermatt A
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28925944
[TBL] [Abstract][Full Text] [Related]
2. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
[TBL] [Abstract][Full Text] [Related]
3. Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
Vuorinen A; Engeli RT; Leugger S; Bachmann F; Akram M; Atanasov AG; Waltenberger B; Temml V; Stuppner H; Krenn L; Ateba SB; Njamen D; Davis RA; Odermatt A; Schuster D
J Nat Prod; 2017 Apr; 80(4):965-974. PubMed ID: 28319389
[TBL] [Abstract][Full Text] [Related]
4. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
[TBL] [Abstract][Full Text] [Related]
5. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
6. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
[TBL] [Abstract][Full Text] [Related]
7. Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Lespérance M; Barbeau X; Roy J; Maltais R; Lagüe P; Poirier D
Steroids; 2018 Dec; 140():104-113. PubMed ID: 30273695
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
9. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
10. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals.
Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A
Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
13. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
14. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges.
Salah M; Abdelsamie AS; Frotscher M
Mol Cell Endocrinol; 2019 Jun; 489():66-81. PubMed ID: 30336189
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.
Deluca D; Möller G; Rosinus A; Elger W; Hillisch A; Adamski J
Mol Cell Endocrinol; 2006 Mar; 248(1-2):218-24. PubMed ID: 16406285
[TBL] [Abstract][Full Text] [Related]
17. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold.
Wetzel M; Marchais-Oberwinkler S; Hartmann RW
Bioorg Med Chem; 2011 Jan; 19(2):807-15. PubMed ID: 21211981
[TBL] [Abstract][Full Text] [Related]
18. Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC
Abdelsamie AS; van Koppen CJ; Bey E; Salah M; Börger C; Siebenbürger L; Laschke MW; Menger MD; Frotscher M
Eur J Med Chem; 2017 Feb; 127():944-957. PubMed ID: 27852458
[TBL] [Abstract][Full Text] [Related]
19. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.
Vuorinen A; Engeli R; Meyer A; Bachmann F; Griesser UJ; Schuster D; Odermatt A
J Med Chem; 2014 Jul; 57(14):5995-6007. PubMed ID: 24960438
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]